EMEA To Get To Heart Of COX-2 Inhibitor Safety Issues At Feb. 14-17 Meeting

The Committee for Medicinal Products for Human Use requests further analyses from Pfizer, Merck and Novartis on the cardiovascular safety of COX-2 inhibitors. Pfizer agrees not to launch celecoxib for in an orphan polyp indication until after completion of EMEA's class safety review.